Chinedu Ebenebe
Max Planck Society
9 Papers
3 Citations
Chinedu Ebenebe is an academic researcher from Max Planck Society. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Regulation of EMAP II by Hypoxia
Susanne Matschurat,Ulrike E. Knies,Veronika Person,Ludger Fink,Benjamin Stoelcker,Chinedu Ebenebe,Heike A. Behrensdorf,Jutta Schaper,Matthias Clauss +8 more
TL;DR: It is demonstrated in vivo that EMAP II mRNA expression is strongly increased in tumor necrosis factor alpha-treated murine meth A fibrosarcomas and in B16 melanomas and in close proximity to areas of tissue necrosis.
78
Estimation of Optimal Nasotracheal Tube Insertion Depth in Neonates Based on Fetal Biometric Measurements
Mariel Selter,Philipp Deindl,Monika Wolf,Jochen Herrmann,Kurt Hecher,Dominique Singer,Chinedu Ebenebe +6 more
TL;DR: Recommendations for neonatal nasotracheal ETT insertion depths based on prenatally available data with the potential to facilitate rapid and accurate intubation of neonates are provided.
2
Recommendations for Peripherally Inserted Central Catheter Insertion Depths in Neonates
Alexandra Luister,Neda Khostwal,Philipp Deindl,Jochen Herrmann,Dominique Singer,Chinedu Ebenebe +5 more
TL;DR: In this paper , the authors developed diagrams and tables for the recommendation of PICC insertion depths in neonates based on anthropometric parameters such as body weight, length, and head circumference.
2
Recommendations for endotracheal tube insertion depths in children
Chinedu Ebenebe,Kristina Schriever,S.G. Apostolidou,Monika Wolf,Jochen Herrmann,Dominique Singer,Philipp Deindl +6 more
TL;DR: In this paper , the authors developed age-based, weight-based and height-based curve charts and tables for ETT insertion depth recommendations in children, and compared the insertion depths predicted by the models with previously published formulae.
Therapeutic Management of COVID-19 in a Pediatric Patient with Neurodegenerative CLN2 Disease and ICV-Enzyme Replacement Therapy: A Case Report.
Christoph Schwering,S.G. Apostolidou,Philipp Deindl,Martin Christner,Johannes K.-M. Knobloch,Jochen Herrmann,Robin Kobbe,Angela Schulz,Dominique Singer,Chinedu Ebenebe +9 more
TL;DR: The 12 years old male patient presented here suffers from neuronal ceroid lipofuscinoses 2 (CLN2) and receives intracerebroventricular enzyme replacement therapy (ICV-ERT) every 14 days and is the first CLN2 patient receiving intraventricular enzymes therapy with COVID-19 who required intensive care treatment and specific therapy.
2